Microsulis tissue ablation systems presented at London meeting

Dr Peter Clegg, from the University of Bath microwave science team, who invented and developed the Microsulis microwave tissue ablation systems for destroying tumours, presented an overview of the success of this technology at the recent 'Changing Worlds Showcase - Impact of University Research' meeting held in London. The Rt Hon David Willetts, MP, the Universities & Science Minister, was the keynote speaker, with over 270 guests from Parliament, government agencies, academia, industry, research and funding bodies. The event showcased different research that has changed the world and touched the lives of millions of people, with 20 case studies from the Universities of Bath, Bristol, Southampton and Surrey.

“This system enables surgeons to extend treatment to liver cancer patients who would not normally have been treated. Ongoing studies suggest significantly improved clinical outcomes for tumour control, adding to our armamentarium.”

In a presentation 'Microwaves in medical therapy: non-invasive treatments for cancer', Dr Clegg discussed how his team's revolutionary British technology succeeded in treating previously untreatable patients with liver and other cancers, where many other technologies had failed.

Stuart McIntyre, CEO of Microsulis commented, "We are pleased to demonstrate to such an important audience how Peter and the team's invention has transformed patient's lives and treatment options. The Accu2i, the latest in our range, has now been successfully launched to an international clinical audience at major medical meetings in Europe and New Zealand and, crucially, many international distributors have now been engaged to expand the worldwide distribution network for the product. Increasing numbers of clinicians around the world are adopting the radically improved performance and ease of use of the Acculis system - moving away from older radiofrequency ablation systems."

The Accu2i pMTA is the most powerful tumour ablation system currently available, combining extreme ease of use with the widest range of clinical applications. The device is a single high power high frequency 2.45GHz microwave needle that can address tumours over 5cm in size in just 6 minutes, and is therefore between 3 to 10 times faster than other systems.

"This system enables surgeons to extend treatment to liver cancer patients who would not normally have been treated. Ongoing studies suggest significantly improved clinical outcomes for tumour control, adding to our armamentarium." said Mr David Lloyd, Consultant HPB Surgeon from Leicester Royal Infirmary who fathered the system along with the University of Bath microwave science team.